Procalcitonin is of little value in the diagnosis or management of cellulitis: baseline levels are generally low, levels may be confounded by impaired renal function and are a poor predictor of improvement of cellulitis. 
. Correlation between the logarithm of serum procalcitonin and other measurements
The size of the correlation coefficient is the degree of correlation between procalcitonin and a variable; the p value gives the degree of statistical likelihood that this correlation is true. *95% CI 0.486, 0.638 Figure 2 . Primary outcome and ROC curves of neutrophil:lymphocyte ratio, procalcitonin, total affected area and C-reactive protein A ROC curve with high sensitivity and high specificity would have a large area under the curve (AUC) and the optimum value would be close to the upper left corner of the chart.
Renal function
• The arithmetic mean procalcitonin of those patients with serum creatinine levels of ≥100µmol/L was 0.25μg/L compared to 0.10 μg/L for those with creatinine of <100µmol/L. • The mean creatinine of those patients with procalcitonin levels of ≥1μg/L was 100µmol/L compared to 77µmol/L for those with procalcitonin of < 1μg/L. • Of the five patients with procalcitonin levels greater than 10μg/L the mean creatinine was 157µmol/L 
STRENGTHS AND LIMITATIONS OF THIS STUDY
• This study uses a wide range of data from a controlled clinical trial • The study allowed follow up over a 10 day period • There was no control group with other limb skin or soft tissue disorders
ClinicalTrials.gov Identifier: NCT01876628
We would particularly like to thank the coordinating research nurses Chiaki Shioi and Louise Wright, and our trial administrator Lucy Dixon. Summary • The neutrophil:lymphocyte ratio was the most strongly correlated with procalcitonin.
• Procalcitonin is a poor predictor of improvement at Day 5 and the return to normal activities at any follow up point.
• We cannot recommend that procalcitonin be used to differentiate cellulitis from other skin disorders which may appear similar to cellulitis.
Methods
This study used data collected as part of a clinical trial of antibiotic therapy for cellulitis (clindamycin for cellulitis, NCT01876628). A subset of the patients recruited into the trial had procalcitonin levels measured at each visit. Procalcitonin levels were statistically correlated with an array of clinical and laboratory measurements. We then selected the variables most strongly correlated with procalcitonin and evaluated the predictive value of the baseline procalcitonin on the primary trial outcome; improvement at the Day 5 follow up and return to normal activities at the three follow up points.
Results
136 patients (109 trial and 27 non-trial patients) with 139 baseline sets of data (111 trial and 28 non-trial patients) provided 314 procalcitonin values which were correlated with 21 variables. The strongest correlations (Pearson correlation coefficient of >0.5) with procalcitonin were the total affected skin area (0.537), C-reactive protein (0.574) and neutrophil:lymphocyte ratio (0.567). ROC curves demonstrated poor sensitivity and specificity of procalcitonin in predicting primary outcome. Patients with impaired renal function were more likely to have high procalcitonin levels.
Background
Procalcitonin is a biochemical marker which is raised in bacterial infections. It has been used to assist in determining whether or not a patient will benefit from antibiotic therapy. Within the context of a clinical trial of antibiotic therapy, we wished to examine the correlation between clinical observations, blood tests and local measurements of skin damage, with serum procalcitonin levels. *Under the nonparametric assumption, **Null hypothesis: true area = 0.5
Normal activities ROC curves ROC curves were generated of procalcitonin levels with the patient being back to normal activities at three follow up points; AUCs were for 0. INTERVENTIONS Flucloxacillin, minimum of 500mg four times per day for five days, with clindamycin 300mg four times per day for two days given orally versus flucloxacillin given alone.
MAIN OUTCOME MEASURES
Primary outcome was improvement at Day 5. This was defined as being afebrile with either a reduction in affected skin surface temperature or a reduction in the circumference of the affected area.
Secondary outcomes included resolution of systemic features, resolution of inflammatory markers, recovery of renal function, reduction in the affected area, decrease in pain, return to work or normal activities and the absence of increased side-effects.
RESULTS
• 410 patients were included in the trial. 
STRENGTHS AND LIMITATIONS OF THIS STUDY
• This was a double-blind randomised multi-centre study and the first to examine the effect of adjunctive clindamycin with betalactam therapy for cellulitis.
• Patients were recruited from general practice, emergency department patients and inpatients and are thus a representative population.
• The study lost 18% of the patients by the first follow-up visit but the characteristics of these patients was similar in both drug allocations.
ClinicalTrials.gov Identifier: NCT01876628
We would particularly like to thank the coordinating research nurses Chiaki Shioi and Louise Wright, and our trial administrator Lucy Dixon.
